Physician profile
Hao Wang
NPI 1093873036
$2,625.50
in general payments reported to CMS, 2019-2025
20 companies · $1,357 in 2025
The $1,357 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $103 · 2020: $198 · 2021: $44.65 · 2022: $43.66 · 2023: $248 · 2024: $631 · 2025: $1,357.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,226 · Education: $9.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,226.34 |
| Education | $9.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $590.88 | 2023-2025 | Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $464.88 | 2020-2025 | Tremfya |
| Ucb, INC. | $221.21 | 2023-2025 | Bimzelx |
| Incyte Corporation | $219.08 | 2023-2025 | Opzelura |
| Galderma Laboratories, L.P. | $211.73 | 2021-2025 | Nemluvio, Aklief |
| Pfizer INC. | $181.57 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $133.32 | 2024-2025 | Libtayo |
| Astrazeneca Pharmaceuticals Lp | $122.31 | 2025 | |
| Nevro Corp. | $102.96 | 2019 | |
| Novartis Pharmaceuticals Corporation | $61.95 | 2023-2025 | |
| Arcutis Biotherapeutics, INC. | $49.30 | 2024 | Zoryve |
| Lilly USA, LLC | $47.35 | 2024-2025 | Taltz, Ebglyss, Zepbound |
| Leo Pharma INC. | $43.66 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $41.82 | 2024-2025 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $33.47 | 2024 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $24.30 | 2023 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.62 | 2024 | Spevigo |
| Biofrontera INC. | $19.22 | 2024 | Xepi, Bf-Rhodoled, Ameluz |
| Organon LLC | $18.59 | 2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $15.28 | 2025 | Jublia, Cabtreo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hao Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.